Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Latest Quinazolines Stories

2013-05-16 08:27:05

Data Presented at American Society of Clinical Oncology (ASCO) on two Boehringer Ingelheim Phase III Oncology Compounds, Afatinib* and Nintedanib*, Show Progression Free Survival in Patients with Advanced Non-Small Cell Lung Cancer BURLINGTON, ON, May 16, 2013 /CNW/ - New research taking place right here on Canadian soil is shedding light on the nation's number one cancer killer,(i) lung cancer.  Boehringer Ingelheim (Canada) Ltd. today announced data from Phase III clinical...

2013-05-15 20:23:01

For U.S. Media Only RIDGEFIELD, Conn., May 15, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced data from two Phase III clinical trials involving two different investigational oncology compounds - afatinib* and nintedanib* - in two distinct patient populations with advanced non-small cell lung cancer (NSCLC). Results from both studies will be presented at the 49(th) Annual Meeting of the American Society of Clinical Oncology (ASCO) in...

2013-05-15 20:22:55

For U.S. Media Only RIDGEFIELD, Conn., May 15, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced the upcoming presentation of data from 14 abstracts involving three of the company's investigational oncology compounds - afatinib*, nintedanib* and volasertib*. Results - to be presented at the 49(th) Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 31-June 4, 2013 - are from Boehringer Ingelheim's robust...

2013-05-08 11:39:52

A seven-year quest to understand how breast cancer cells resist treatment with the targeted therapy lapatinib has revealed a previously unknown molecular network that regulates cell death. The discovery provides new avenues to overcome drug resistance, according to researchers at Duke Cancer Institute. "We've revealed multiple new signaling pathways that regulate cell death," said Sally Kornbluth, PhD, vice dean of Basic Science and professor of Pharmacology and Cancer Biology at Duke...

2013-04-09 11:44:13

Is the era of targeted therapy for breast cancer at hand? It could be, said experts at the Lester and Sue Smith Breast Center at Baylor College of Medicine — at least for a certain population of women. In a report that appears online today in the Journal of Clinical Oncology, the researchers have shown that a subset of breast cancer patients who have tumors overexpressing a protein called the human epidermal growth factor receptor 2 (HER-2 positive) may benefit from a combination of...

2013-04-08 12:28:40

NT-113 is an Irreversible, Selective Pan-ErbB Tyrosine Kinase Inhibitor with Significant Capacity to Cross Blood Brain Barrier MENLO PARK, Calif., April 8, 2013 /PRNewswire/ -- Preclinical data showing high potency, excellent pharmacokinetics and single-agent anti-cancer activity of NT-113, a novel irreversible Pan-ErbB Tyrosine Kinase Inhibitor under development by NewGen Therapeutics, was presented in a poster session today at the American Association of Cancer Research Meeting in...

2013-04-04 08:28:31

CAMBRIDGE, Mass., April 4, 2013 /PRNewswire-USNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) today announced that one cohort of a Phase 2 non-small cell lung cancer (NSCLC) study did not meet its primary endpoint. The cohort evaluated MM-121 in combination with erlotinib to treat patients with NSCLC whose disease progressed on an anti-EGFR tyrosine kinase inhibitor (EGFR-TKI). MM-121 is being evaluated in two additional NSCLC cohorts as well as Phase 2 studies for the treatment of...

New Drug To Treat Breast Cancer Approved By US Regulatory Agency
2013-02-23 06:52:31

April Flowers for redOrbit.com - Your Universe Online The Food and Drug Administration (FDA) has approved a brand new type of breast cancer medication this week that targets tumor cells while sparing healthy surrounding tissues. In U.S. women, breast cancer is the second most deadly form of cancer and is expected to kill more than 39,000 Americans this year alone, the National Cancer Institute reports. Kadcyla, from Roche, is a combination of a powerful chemotherapy drug, the...

2013-02-05 08:35:30

SAN FRANCISCO, Feb. 5, 2013 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today the start of a Phase 2 investigator-initiated study of etirinotecan pegol in patients with metastatic and recurrent NSCLC. The study is being conducted at the Abramson Cancer Center of the University of Pennsylvania under the direction of Charu Aggarwal, M.D., M.P.H., Assistant Professor of Oncology and Corey Langer, M.D., Professor of Oncology. "Patients with metastatic or recurrent non-small cell...

2013-01-15 07:18:20

HILDEN, Germany and GERMANTOWN, Maryland, January 15, 2013 /PRNewswire/ -- - U.S. submission of therascreen(R) EGFR RGQ PCR Kit is paired with FDA submission of afatinib, an investigational tyrosine kinase inhibitor developed by Boehringer Ingelheim - Companion diagnostic intended to aid treatment decisions in non-small cell lung cancer - QIAGEN continues to expand Personalized Healthcare portfolio and content menu...